Optimized Saffron with Satiereal® 60 caps by Life Extension
Optimized Saffron with Satiereal®
88.25mg, 60 vegetarian capsules
Item Catalog Number: 01432
Oral saffron extract seems to reduce eye pressure in glaucoma, according to several studies. The most recent result was reported at the World Ophthalmology Congress 2014 Tokyo. In this report, the intraocular pressure (IOP) reduction became evident after three weeks of therapy. The full abstract is copied below.
Another benefit of saffron is appetite control, as reported by Dr. Oz and others. Do you often find yourself snacking between meals? Are you having difficulty exercising portion control? Optimized Saffron with Satiereal® may be just the answer you need.
Satiereal® is a clinically studied, proprietary extract of saffron... a spice that’s been prized since ancient Persia as a way to enhance mood and relieve stress.84,85
Previously available only in Europe, this standardized saffron extract provides support for healthy body weight by targeting some of the emotional factors that make you eat more when you’re trying to eat less.
Just two 88.25 mg capsules of Optimized Saffron with Satiereal® delivers the active constituents safranal and crocin, shown to modulate certain serotonergic receptors in the brain to support mood.86-89
Satiereal® is a registered trademark of INOREAL. International Patents Pending.
|Dosage and Use|
Do not exceed recommended dose. Consult with your healthcare practitioner before using this product if you are taking anti-coagulant or anti-platelet medications or if you have a bleeding disorder or kidney disease. Avoid use during pregnancy.
To report a serious adverse event or obtain product information, contact 1-866-280-2852
Saffron is a wonderful spice with numerous benefits such as balanced mood and emotions. Some studies suggest that saffron might be as effective as taking a low-dose prescription antidepressant such as fluoxetine or imipramine.
However, its role in Alzheimer’s disease might be of just as much interest to us as its ocular hypotensive effects. Some research shows that taking saffron might improve Alzheimer’s symptoms about as well as the prescription drug donepezil (Aricept) over 22 weeks of treatment, according to WebMD.
However, when it comes to saffron great caution is required because there is a tremendous amount of fraud in the saffron market. Saffron is so easy to emulate and the market price for it is high, so fake saffron is everywhere. If it’s cheap, it’s probably fake. For these reasons, I am recommending Satiereal®, the clinically studied, proprietary extract of saffron.
In clinical studies,90,91 women taking Satiereal® experienced:
- 100% reduction in the desire to snack
- 50% fewer instances of eating between meals
- Less hunger
- Moderate weight loss
- More energy
- Better mood
They experienced a greater sense of control over between-meal snacking, and a change in eating behavior, without that “jittery feeling” or other undesirable effects.91 They reported feeling better about themselves and better in general.
The fact that Satiereal® induced significant reductions (100%) in the desire to snack, but with only moderate weight loss, is further support for the multi-pronged approach needed to effectively manage weight that has long been espoused by Life Extension®.
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Results may vary.
The Ocular Hypotensive Effect of Saffron Extract in Primary Open-Angle Glaucoma: A Pilot Study
To evaluate the effect of aqueous saffron extract on intraocular pressure (IOP) in primary open-angle glaucoma (POAG).
Thirty-four eyes of 34 consecutive patients with POAG under treatment with topical timolol and dorzolamide, were randomized to receive 30 mg/d aqueous saffron extract for one month (17 eyes) While the other 17 eyes served as the control group. Following the treatment period, both groups entered a one-month wash-out period. Main outcome measure was IOP during treatment period and after the wash-out period
Prospective, comparative, randomized interventional case series
Results and Conclusion
Mean baseline IOP (Corneal thickness adjusted IOP) before intervention was 14.23±3.49 mmHg in the saffron group versus 15.52±2.18 mmHg in the control group (p=0.20). After three weeks of treatment, IOP was significantly decreased to 12.29±3.42mmHg in the saffron group as compared to 15.05 ± 2.13mmHg in the control group (p=0.008). At four weeks IOP was significantly lower in the saffron group (11.94±3.15 mmHg versus 15.35±1.86 mmHg in the saffron and control groups respectively, p=0.001). At the end of the wash-out period, IOP was 14.29±2.80 in the saffron group and 15.70±1.72 mmHg in the control group (p=0.086).
None of enrolled patients had adverse effects. Oral aqueous saffron extract seems to have ocular hypotensive effect in POAG. This effect became evident after three weeks of therapy.